Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gopa Iyer

Showing results (21-30 of 144) with videos related to

Pageof 15
Sort By:
Frontiers in Oncology|February 28, 2025
Case report: Clinical and molecular features of renal gastrointestinal tumorSimran Makker, Rayan Rammal, Ping Gu, et al.
Current Oncology (Toronto, Ont.)|February 25, 2025
Immune Checkpoint Blockade Response in Mucinous Tubular and Spindle Cell CarcinomaSimran Makker, Neil J Shah, Maria I Carlo, et al.
Oncotarget|November 9, 2017
Activating mutation of <i>PDGFRB</i> gene in a rare cardiac undifferentiated intimal sarcoma of the left atrium: a case reportXiaoling Fu, Weixin Niu, Ji Li, et al.
Translational Cancer Research|February 4, 2022
"Primary" and "secondary" muscle-invasive bladder cancer is more than just a surrogate for molecular subtypesEugene J Pietzak, Hikmat Al-Ahmadie, Aleksandra Walasek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2014
Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumorsDarren R Feldman, Gopa Iyer, Lindsay Van Alstine, et al.
Oncotarget|July 10, 2018
Lysis-independent potentiation of immune checkpoint blockade by oncolytic virusAnton Oseledchyk, Jacob M Ricca, Mathieu Gigoux, et al.
Cancer Investigation|November 9, 2016
Tumor Inhibition by Enzalutamide in a Xenograft Model of Ovarian CancerBrian Y Park, Rachel N Grisham, Bjørnar den Hollander, et al.
Scientific Reports|January 20, 2022
Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancerSushmita B Gordhandas, Beryl Manning-Geist, Christina Henson, et al.
Ophthalmology. Retina|June 8, 2021
Clinical and Morphologic Characteristics of Extracellular Signal-Regulated Kinase Inhibitor-Associated RetinopathyJasmine H Francis, Julia Canestraro, Dianna Haggag-Lindgren, et al.
JAMA Dermatology|July 30, 2025
Use of Dupilumab to Manage Antibody-Drug Conjugate-Induced Cutaneous ToxicitiesIan Nykaza, Stephen W Dusza, Jonathan E Rosenberg, et al.
Pageof 15

Showing results (21-30 of 144) with videos related to

Sort By:
Pageof 15
Frontiers in Oncology|February 28, 2025
Case report: Clinical and molecular features of renal gastrointestinal tumorSimran Makker, Rayan Rammal, Ping Gu, et al.
Current Oncology (Toronto, Ont.)|February 25, 2025
Immune Checkpoint Blockade Response in Mucinous Tubular and Spindle Cell CarcinomaSimran Makker, Neil J Shah, Maria I Carlo, et al.
Oncotarget|November 9, 2017
Activating mutation of <i>PDGFRB</i> gene in a rare cardiac undifferentiated intimal sarcoma of the left atrium: a case reportXiaoling Fu, Weixin Niu, Ji Li, et al.
Translational Cancer Research|February 4, 2022
"Primary" and "secondary" muscle-invasive bladder cancer is more than just a surrogate for molecular subtypesEugene J Pietzak, Hikmat Al-Ahmadie, Aleksandra Walasek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2014
Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumorsDarren R Feldman, Gopa Iyer, Lindsay Van Alstine, et al.
Oncotarget|July 10, 2018
Lysis-independent potentiation of immune checkpoint blockade by oncolytic virusAnton Oseledchyk, Jacob M Ricca, Mathieu Gigoux, et al.
Cancer Investigation|November 9, 2016
Tumor Inhibition by Enzalutamide in a Xenograft Model of Ovarian CancerBrian Y Park, Rachel N Grisham, Bjørnar den Hollander, et al.
Scientific Reports|January 20, 2022
Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancerSushmita B Gordhandas, Beryl Manning-Geist, Christina Henson, et al.
Ophthalmology. Retina|June 8, 2021
Clinical and Morphologic Characteristics of Extracellular Signal-Regulated Kinase Inhibitor-Associated RetinopathyJasmine H Francis, Julia Canestraro, Dianna Haggag-Lindgren, et al.
JAMA Dermatology|July 30, 2025
Use of Dupilumab to Manage Antibody-Drug Conjugate-Induced Cutaneous ToxicitiesIan Nykaza, Stephen W Dusza, Jonathan E Rosenberg, et al.
Pageof 15